MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinsonism"

  • 2019 International Congress

    Modeling of Parkinson’s disease by damaging dopaminergic neurons

    L. Toshpulatova, M. Kulmanova (Tashkent, Uzbekistan)

    Objective: Analysis of the simulation of Parkinson's disease in rats using 6-OHDA.Analysis of the simulation of Parkinson's disease in rats using 6-OHDA. Background: The mechanism…
  • 2019 International Congress

    Spectrum of parkinsonian phenotypes associated with GCH1 mutation.

    D. Al-Shorafat, A. Shetty, D. Munoz, A. Fasano, A. Lang (Toronto, ON, Canada)

    Objective: To describe the heterogeneity of parkinsonism in patients with GCH1 mutations. Background: Dopa-responsive dystonia (DRD) is an inherited disorder that responds dramatically to levodopa…
  • 2019 International Congress

    Daytime Sleepiness Effects on Motor Symptoms in De Novo Parkinson’s Disease

    E. Bayram, R. Yilmaz, K. Longardner, M. Akbostanci, I. Litvan (La Jolla, CA, USA)

    Objective: To investigate whether daytime sleepiness in newly diagnosed Parkinson’s disease (PD) patients predicts future dependency. Background: Excessive daytime sleepiness (EDS) is one of the…
  • 2019 International Congress

    Effect of a Combined Treatment with Botulinum Toxin and Biofeedback Exercises in Pisa Syndrome

    A. Castagna, A. Crippa, D. Anastasi, M. Meloni, A. Montesano, A. Marzegan (Milano, Italy)

    Objective: To assess the efficacy of a combined botulinum neurotoxin (BoNT) treatment with biofeedback exercises in a single Parkinson Disease (PD) patient with Pisa Syndrome…
  • 2019 International Congress

    Attentional Intervention to Improve Cognition and Gait in Parkinson’s Disease: Side of Onset Effects

    A. Cronin-Golomb, O. Barthelemy, A. Marin, B. Davis, S. Alshuaib, T. Ellis, J. Degutis (Boston, MA, USA)

    Objective: To establish whether home-based computerized attentional training would improve cognition, gait, and function in Parkinson’s disease (PD). Background: Impairments in cognition and gait are…
  • 2019 International Congress

    Levodopa response in later stages of Parkinson’s disease: a case-control study

    M. Fabbri, M. Coelho, D. Abreu, L. Guedes, M. Rosa, A. Antonini, J. Ferreira (Lisbon, Portugal)

    Objective: To compare the response of motor and non-motor symptoms (NMS) to a L-dopa challenge test  between late stage (LS) PD patients and advanced stage…
  • 2019 International Congress

    Effect of Levodopa on gut microbiome in Parkinson’s Disease (PD)

    A. Hannoun, D. Ward, J. Flahive, J. Friedman, A. Deb, K. Smith (Worcester, MA, USA)

    Objective: To characterize changes in the gut microbiome in de novo PD subjects before and after initiating carbidopa/levodopa Background: The gastrointestinal microbiome in patients with…
  • 2019 International Congress

    Vascular Parkinsonism and Parkinson’s Disease: clinical differences concerning balance impairment

    R. Jesus, R. Raimundo, C. Azoia, M. Mendes, V. Espirito-Santo, A. Almeida, I. Rego, AG. Velon (Vila Real, Portugal)

    Objective: Determine and compare lower body predominance and balance between Vascular Parkinsonism (VP) and Parkinson’s Disease (PD)patients in a hospital-based sample. Background: Despite the recognition…
  • 2019 International Congress

    Is the personal Kinetigraph useful in the management of Parkinson´s disease patients? A retrospective study from a tertiary movement disorder center

    E. Krause, J. Randhawa, R. Mehanna (Houston, TX, USA)

    Objective: To assess the usefulness of the Personal KinetiGraph (PKG) in characterizing the intensity and timing of motor symptoms in Parkinson´s Disease (PD) patients. Background:…
  • 2019 International Congress

    Correlation Between PDQ-39 and MDS-UPDRS Scores in a Phase 3 Randomized Controlled Trial of Patients with Parkinson’s Disease

    T. Lokhandwala, A. Lee, B. Yue, A. Thach, B. Navia (Palm Harbor, FL, USA)

    Objective: To describe correlations of the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part III scores with the 39-item Parkinson’s disease (PD) questionnaire…
  • « Previous Page
  • 1
  • …
  • 151
  • 152
  • 153
  • 154
  • 155
  • …
  • 405
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley